In an end-of-year IPO blitz, 4 biotechs pitch new offerings totaling $370M
An immuno-oncology company focused on a more potent T cell attack. Two biotechs that grabbed assets off the remaindered shelves at Big Pharma. And one gene therapy upstart looking to cure Duchenne muscular dystrophy, one of the most controversial fields in biopharma R&D.
Altogether, the group of 4 mounted a last minute wave of IPO filings during the waning hours of 2017. And if they come even close to raising the $370 million pencilled in for their S-1s we’ll have a good idea whether the venture-backed brigade of private biotechs can continue a solid run that sparked up the second half of last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
